Novel Gene Signatures Predicting Primary Non-response to Infliximab in Ulcerative Colitis: Development and Validation Combining Random Forest With Artificial Neural Network

Background: While infliximab has revolutionized the treatment of ulcerative colitis, primary non-response is difficult to predict, which limits effective disease management. The study aimed to establish a novel genetic model to predict primary non-response to infliximab in patients with ulcerative c...

Descripción completa

Detalles Bibliográficos
Autores principales: Feng, Jing, Chen, Yueying, Feng, Qi, Ran, Zhihua, Shen, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8505970/
https://www.ncbi.nlm.nih.gov/pubmed/34650991
http://dx.doi.org/10.3389/fmed.2021.678424

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8505970/
https://www.ncbi.nlm.nih.gov/pubmed/34650991
http://dx.doi.org/10.3389/fmed.2021.678424

Ejemplares similares